S&P 500   3,960.27 (+0.67%)
DOW   33,719.47 (+0.36%)
QQQ   283.23 (+0.96%)
AAPL   141.98 (+0.74%)
MSFT   246.69 (+0.95%)
META   115.51 (+1.39%)
GOOGL   94.03 (-0.96%)
AMZN   89.79 (+1.50%)
TSLA   172.39 (-0.95%)
NVDA   169.16 (+4.94%)
NIO   13.32 (+5.88%)
BABA   94.02 (+6.44%)
AMD   69.77 (-0.53%)
T   19.12 (-0.93%)
MU   55.14 (+2.45%)
CGC   2.99 (-7.72%)
F   13.11 (+0.08%)
GE   83.24 (-2.07%)
DIS   92.34 (+0.21%)
AMC   6.14 (+1.49%)
PYPL   74.22 (-0.27%)
PFE   51.68 (+2.87%)
NFLX   308.23 (-0.06%)
S&P 500   3,960.27 (+0.67%)
DOW   33,719.47 (+0.36%)
QQQ   283.23 (+0.96%)
AAPL   141.98 (+0.74%)
MSFT   246.69 (+0.95%)
META   115.51 (+1.39%)
GOOGL   94.03 (-0.96%)
AMZN   89.79 (+1.50%)
TSLA   172.39 (-0.95%)
NVDA   169.16 (+4.94%)
NIO   13.32 (+5.88%)
BABA   94.02 (+6.44%)
AMD   69.77 (-0.53%)
T   19.12 (-0.93%)
MU   55.14 (+2.45%)
CGC   2.99 (-7.72%)
F   13.11 (+0.08%)
GE   83.24 (-2.07%)
DIS   92.34 (+0.21%)
AMC   6.14 (+1.49%)
PYPL   74.22 (-0.27%)
PFE   51.68 (+2.87%)
NFLX   308.23 (-0.06%)
S&P 500   3,960.27 (+0.67%)
DOW   33,719.47 (+0.36%)
QQQ   283.23 (+0.96%)
AAPL   141.98 (+0.74%)
MSFT   246.69 (+0.95%)
META   115.51 (+1.39%)
GOOGL   94.03 (-0.96%)
AMZN   89.79 (+1.50%)
TSLA   172.39 (-0.95%)
NVDA   169.16 (+4.94%)
NIO   13.32 (+5.88%)
BABA   94.02 (+6.44%)
AMD   69.77 (-0.53%)
T   19.12 (-0.93%)
MU   55.14 (+2.45%)
CGC   2.99 (-7.72%)
F   13.11 (+0.08%)
GE   83.24 (-2.07%)
DIS   92.34 (+0.21%)
AMC   6.14 (+1.49%)
PYPL   74.22 (-0.27%)
PFE   51.68 (+2.87%)
NFLX   308.23 (-0.06%)
S&P 500   3,960.27 (+0.67%)
DOW   33,719.47 (+0.36%)
QQQ   283.23 (+0.96%)
AAPL   141.98 (+0.74%)
MSFT   246.69 (+0.95%)
META   115.51 (+1.39%)
GOOGL   94.03 (-0.96%)
AMZN   89.79 (+1.50%)
TSLA   172.39 (-0.95%)
NVDA   169.16 (+4.94%)
NIO   13.32 (+5.88%)
BABA   94.02 (+6.44%)
AMD   69.77 (-0.53%)
T   19.12 (-0.93%)
MU   55.14 (+2.45%)
CGC   2.99 (-7.72%)
F   13.11 (+0.08%)
GE   83.24 (-2.07%)
DIS   92.34 (+0.21%)
AMC   6.14 (+1.49%)
PYPL   74.22 (-0.27%)
PFE   51.68 (+2.87%)
NFLX   308.23 (-0.06%)
NASDAQ:SURF

Surface Oncology - SURF Stock Forecast, Price & News

$0.84
+0.00 (+0.58%)
(As of 12/8/2022 02:29 PM ET)
Add
Compare
Today's Range
$0.84
$0.87
50-Day Range
$0.84
$1.35
52-Week Range
$0.84
$5.98
Volume
859 shs
Average Volume
270,986 shs
Market Capitalization
$51.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.60

Surface Oncology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
682.0% Upside
$6.60 Price Target
Short Interest
Healthy
1.90% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.08) to ($1.47) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

499th out of 1,027 stocks

Biological Products, Except Diagnostic Industry

81st out of 171 stocks

SURF stock logo

About Surface Oncology (NASDAQ:SURF) Stock

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Receive SURF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surface Oncology and its competitors with MarketBeat's FREE daily newsletter.

SURF Stock News Headlines

Recap: Surface Oncology Q3 Earnings
Surface Oncology Inc (SURF)
Surface Oncology, Inc. (SURF)
Surface Oncology: Q2 Earnings Insights
See More Headlines
Receive SURF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surface Oncology and its competitors with MarketBeat's FREE daily newsletter.

SURF Company Calendar

Last Earnings
11/04/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/01/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SURF
Fax
N/A
Employees
67
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.60
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+681.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-78,490,000.00
Net Margins
-182.63%
Pretax Margin
-219.88%

Debt

Sales & Book Value

Annual Sales
$2.69 million
Book Value
$2.58 per share

Miscellaneous

Free Float
53,277,000
Market Cap
$51.16 million
Optionable
Not Optionable
Beta
1.63

Key Executives

  • Dr. Robert W. Ross M.D. (Age 48)
    Pres, CEO & Director
    Comp: $813.01k
  • Dr. Vito J. Palombella Ph.D. (Age 59)
    Chief Scientific Officer
    Comp: $633.25k
  • Dr. Alison O'Neill M.D. (Age 61)
    Chief Medical Officer
    Comp: $649.67k
  • Ms. Jessica Fees CPA (Age 51)
    CFO & Treasurer
  • Ms. Theresa R. Boni J.D. (Age 54)
    Gen. Counsel, Sec. & Sr. VP of Legal
  • Ms. Lisa McGrath
    Chief People Officer
  • Mr. Henry C. Rath (Age 51)
    Chief Bus. Officer
  • Ms. Shannon Rourke Devens
    Sr. VP of Devel. Operations













SURF Stock - Frequently Asked Questions

Should I buy or sell Surface Oncology stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SURF shares.
View SURF analyst ratings
or view top-rated stocks.

What is Surface Oncology's stock price forecast for 2023?

2 equities research analysts have issued 12-month price targets for Surface Oncology's shares. Their SURF share price forecasts range from $3.00 to $12.00. On average, they anticipate the company's share price to reach $6.60 in the next year. This suggests a possible upside of 682.0% from the stock's current price.
View analysts price targets for SURF
or view top-rated stocks among Wall Street analysts.

How have SURF shares performed in 2022?

Surface Oncology's stock was trading at $4.78 at the beginning of the year. Since then, SURF stock has decreased by 82.3% and is now trading at $0.8440.
View the best growth stocks for 2022 here
.

When is Surface Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 1st 2023.
View our SURF earnings forecast
.

How were Surface Oncology's earnings last quarter?

Surface Oncology, Inc. (NASDAQ:SURF) released its earnings results on Thursday, November, 4th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $0.04. The company earned $0.39 million during the quarter. Surface Oncology had a negative net margin of 182.63% and a negative trailing twelve-month return on equity of 52.58%.

What is Jeff Goater's approval rating as Surface Oncology's CEO?

5 employees have rated Surface Oncology Chief Executive Officer Jeff Goater on Glassdoor.com. Jeff Goater has an approval rating of 100% among the company's employees. This puts Jeff Goater in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Surface Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surface Oncology investors own include Pfizer (PFE), CrowdStrike (CRWD), QUALCOMM (QCOM), Fastly (FSLY), Intel (INTC), Hello Group (MOMO), NVIDIA (NVDA), U.S. Xpress Enterprises (USX), Xilinx (XLNX) and Genocea Biosciences (GNCA).

When did Surface Oncology IPO?

(SURF) raised $84 million in an IPO on Thursday, April 19th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI served as the underwriters for the IPO.

What is Surface Oncology's stock symbol?

Surface Oncology trades on the NASDAQ under the ticker symbol "SURF."

Who are Surface Oncology's major shareholders?

Surface Oncology's stock is owned by a variety of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (10.40%), EcoR1 Capital LLC (6.48%), Vanguard Group Inc. (3.81%), Sumitomo Mitsui Trust Holdings Inc. (1.90%), Renaissance Technologies LLC (1.63%) and Barclays PLC (0.72%). Insiders that own company stock include David S Grayzel, Henry C Rath, Jeff Goater, Jessica Fees and Robert W Ross.
View institutional ownership trends
.

How do I buy shares of Surface Oncology?

Shares of SURF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Surface Oncology's stock price today?

One share of SURF stock can currently be purchased for approximately $0.84.

How much money does Surface Oncology make?

Surface Oncology (NASDAQ:SURF) has a market capitalization of $51.10 million and generates $2.69 million in revenue each year. The company earns $-78,490,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis.

How can I contact Surface Oncology?

Surface Oncology's mailing address is 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.surfaceoncology.com. The company can be reached via phone at (617) 714-4096 or via email at ir@surfaceoncology.com.

This page (NASDAQ:SURF) was last updated on 12/8/2022 by MarketBeat.com Staff